Design, generation and production of AAV and adenovirus vectors

The research group has large experience in the design, development, generation, production, and characterization of AAV and adenovirus vectors at preclinical level, demonstrated by a significant number of scientific articles in gene therapy, granted projects, patents and in the creation of 2 spin-off companies in gene therapy.

With 30 years of experience in AAV and adenovirus vectors, our research group has the capacity to generate a wide range of different viral vectors, a proven track record in both preclinical and clinical studies, as well as an active research and development lines for procedure optimization and construction of AAV vector libraries. As a result, our group is one of the only 6 gene therapy groups participating in the Network of Excellence on Advanced Therapies (RICORS-TERAV) financed by the Instituto de Salud Carlos III (ISCIII).

Vector Production Unit -UPV-

The technological advances on gene therapy vectors generated and/or set up by the research group are implemented into the UPV, a technological Platform created by our research group, which is specialized in the cloning, production and purification of adenovirus and adeno-associated virus (AAV) serotypes for public institutions and private companies all over the world (more than 2000 batches in the last years).

To highlight that the UPV has a quality assurance system compliant with ISO 9001:2015 requirements since August 23, 2018. It also holds the TECNIO Quality accreditation from the Generalitat de Catalunya since 2018.